Report
Note: Workshop Summaries contain the opinion of the presenters, but do NOT reflect the conclusions of the IOM. Learn more about the differences between Workshop Summaries and Consensus Reports.
Although the cost of research and development for new drugs has increased 50-fold since 1970, the success rate for developing new drugs has not improved. In fields such as oncology, in which patients’ survival may depend on new treatments, there is an urgent need to find a more productive way to develop drugs through cooperation among industry, academia, government, and philanthropic organizations. One solution may be increased precompetitive collaboration, or the collaboration among competitors to achieve goals with the potential to benefit everyone, in oncology drug development. Such collaboration would allow institutions to pool resources and expertise for the multidisciplinary research necessary for drug development. In addition, groups working toward similar objectives could learn from one another’s successes and failures, furthering progress toward a shared goal.
The IOM’s National Cancer Policy Forum held a workshop February 9-10, 2010, to explore the benefits and challenges of precompetitive collaboration. Speakers offered lessons learned and best practices as well as steps to increase collaboration in oncology drug development. This document summarizes the workshop.
Other Reports by this Activity
Displaying: 3 of 15 Reports
-
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies - Workshop Summary
Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies. The IOM’s National Cancer Policy Forum held a workshop to discuss challenges and identify potential solutions to improve collaboration and advance the development of combination investigational cancer therapies.
Released: October 31, 2011
-
Implementing a National Cancer Clinical Trials System for the 21st Century - Workshop Summary
The National Cancer Institute’s Clinical Trials Cooperative Group Program works to advance patient care and research. Despite broad participation in the program, financial strain and procedural burdens limit the ability of the Cooperative Group Program to undertake medical practice-changing clinical research. The IOM’s National Cancer Policy Forum and the American Society of Clinical Oncology held a workshop on March 21, 2011 to follow up on the 2010 IOM report A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, which made recommendations to strengthen the NCI Cooperative Group Program.
Released: July 22, 2011
-
Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care - Workshop Summary
The life-threatening nature of cancer and the complexity of cancer treatment options, each with its own set of potential risks and benefits, make it difficult for people with cancer to make decisions about their care. A cancer treatment plan—a written document describing the path of care and who is responsible for each portion of that care—can provide patients with a roadmap to navigate the uncertain path they face. However, most providers lack the tools, time, and resources needed to efficiently and effectively prepare such plans with their patients. The IOM’s National Cancer Policy Forum held a workshop to discuss ways to create a more coordinated, patient-centered cancer treatment planning process.
Released: June 13, 2011
Future Meeting for this Activity
View Agenda
Previous Meeting for this Activity